In this proposal, the authors aim to assess the effect of canagliflozin compared to placebo on liver-related outcomes in patients with T2DM and to identify subgroups that benefit most from such treatments. This is a realistic proposal, however, in order to help improve clarify, the authors should provide more information about how they will develop the prediction score – how will variables be selected, etc.
Recommendation for this data request: Approve